Logo

RCKT

Rocket Pharmaceuticals, Inc.

RCKT

Rocket Pharmaceuticals, Inc. • NASDAQ
$3.44 ▲ 4.41% (+0.14)
Market Cap $371.74 M
52w High $15.00
52w Low $2.19
Dividend Yield 0%
P/E -1.43
Volume 1.11M
Outstanding Shares 108.22M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $52.247M ▼ $-50.332M ▲ 0% $-0.45 ▲ $-46.619M ▲
Q2-2025 $0 $71.149M ▲ $-68.919M ▼ 0% $-0.62 ▼ $-65.867M ▼
Q1-2025 $0 $64.388M ▲ $-61.334M ▼ 0% $-0.56 ▲ $-57.873M ▼
Q4-2024 $0 $62.694M ▼ $-60.327M ▲ 0% $-0.62 ▲ $-57.493M ▲
Q3-2024 $0 $69.424M $-66.719M 0% $-0.71 $-63.859M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $222.758M ▼ $368.033M ▼ $54.364M ▼ $313.669M ▼
Q2-2025 $271.494M ▼ $420.979M ▼ $66.768M ▲ $354.211M ▼
Q1-2025 $318.164M ▼ $471.066M ▼ $58.928M ▼ $412.138M ▼
Q4-2024 $372.336M ▲ $527.7M ▲ $64.466M ▲ $463.234M ▲
Q3-2024 $235.662M $393.688M $63.917M $329.771M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-50.332M ▲ $-50.428M ▼ $93.616M ▲ $-59K ▼ $43.129M ▲ $-50.374M ▼
Q2-2025 $-68.919M ▼ $-48.964M ▲ $31.761M ▲ $215K ▲ $-16.988M ▲ $-49.014M ▲
Q1-2025 $-61.334M ▼ $-55.802M ▼ $-58.035M ▼ $12K ▼ $-113.825M ▼ $-56.166M ▼
Q4-2024 $-60.327M ▲ $-46.957M ▲ $-37.871M ▼ $182.864M ▲ $98.036M ▲ $-47.266M ▲
Q3-2024 $-66.719M $-52.103M $78.919M $176K $26.992M $-53.691M

Five-Year Company Overview

Income Statement

Income Statement Rocket is still a pure R&D story: it has essentially no product revenue yet and lives entirely on research and development spending. Losses have been consistent and have grown over time as the company has expanded its pipeline and development activities. More recently, the size of the loss appears to be stabilizing rather than accelerating, but it is still substantial. This profile is typical of a clinical‑stage biotech that is investing heavily ahead of any commercial launches, and profitability depends on successful approvals and eventual sales, which remain uncertain in timing and scale.

Balance Sheet

Balance Sheet The balance sheet shows a business financed mostly by shareholder equity with only a small amount of debt, which limits financial leverage risk but keeps the focus on future equity or partnership funding. Overall assets and equity have stayed in a similar range over several years, suggesting no dramatic buildup of physical assets or acquisitions. Cash levels have moved up and down as the company raises funds and then spends them on trials and facilities, with a recent improvement from prior lows. The modest debt and solid equity base are positives, but the key constraint is how long the existing cash can support ongoing clinical programs before new capital is needed.

Cash Flow

Cash Flow Rocket consistently uses cash rather than generating it, as expected for a company without approved products. Operating cash outflows have grown over time, reflecting deeper investment in clinical trials, manufacturing, and staff. Free cash flow is also firmly negative, and capital spending, while relatively small, adds to the cash burn. The business model today is essentially: raise capital, invest in trials and infrastructure, and hope that future approvals eventually flip the cash profile; until then, investors should expect continued cash consumption and periodic funding needs.

Competitive Edge

Competitive Edge Rocket operates in a highly specialized niche within gene therapy, focusing on rare cardiovascular and blood disorders where there are few or no approved treatments. Its dual‑platform approach (AAV for heart diseases and lentiviral for blood disorders) and in‑house manufacturing provide clear technical and operational advantages versus many smaller peers that must outsource production. The focus on rare, severe diseases often brings regulatory incentives and less direct competition from the largest pharma companies, giving Rocket a path to “first‑in‑class” or “best‑in‑class” positioning in several indications. On the other hand, it faces capable competitors in gene therapy and has already encountered serious clinical and regulatory setbacks, which highlight how fragile competitive advantages can be in this space. The company’s long‑term position will depend heavily on whether it can convert its early scientific lead into approved products with compelling safety and durability of effect.

Innovation and R&D

Innovation and R&D Innovation is at the core of Rocket’s identity: it uses both viral vector types, tailors them to each disease, and operates a large, modern facility that lets it control complex gene‑therapy manufacturing from end to end. Its pipeline spans multiple rare diseases, including Danon disease and certain inherited cardiomyopathies, with some of the most advanced clinical data globally in monogenic heart conditions. The company’s lentiviral programs in blood disorders have shown strong survival outcomes in trials, and the softer pre‑treatment approach may offer a safety edge if regulators ultimately agree. However, the recent clinical hold and a patient death in Danon disease, the withdrawal of the Fanconi Anemia filing, and the regulatory delay for KRESLADI all underline the high scientific and regulatory risk of this field. Overall, Rocket is pushing the frontiers of gene therapy, but its R&D pathway is bumpy and outcomes remain highly uncertain.

Summary

Rocket Pharmaceuticals is a classic high‑risk, high‑potential clinical‑stage biotech: no current product revenue, substantial and sustained losses, and heavy investment in cutting‑edge gene therapies for rare diseases. Financially, the company appears reasonably conservatively structured, with limited debt and a balance sheet that has so far supported significant R&D and infrastructure building, but its cash flows are deeply negative and will likely remain so until at least one program reaches the market. Strategically, Rocket’s dual‑platform technology, rare‑disease focus, and in‑house manufacturing give it a meaningful edge in a difficult and specialized area of medicine. At the same time, recent clinical and regulatory setbacks show how fragile progress can be in gene therapy and how much hinges on safety, manufacturing quality, and regulatory trust. The company’s future will largely be determined by the resolution of its Danon disease program issues, regulatory decisions for KRESLADI, and the ability of its cardiovascular pipeline to deliver clear, durable patient benefits that can translate into commercial success.

NEWS

November 25, 2025 · 7:00 AM UTC

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Read more

November 6, 2025 · 4:00 PM UTC

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Read more

October 23, 2025 · 6:03 PM UTC

ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Read more

October 14, 2025 · 7:00 AM UTC

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Read more

October 10, 2025 · 4:00 PM UTC

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more